
|Articles|April 26, 2004
Series of studies explore safety and efficacy of anti-VEGF monoclonal antibody treatment for exudative AMD
Two Phase III studies are now underway evaluating ranibizumab (formerlyrhu Fab V2, Lucentis; Genentech) for the treatment of exudative age-relatedmacular degeneration (AMD). The studies are based on Phase I/II study results,demonstrating it is well tolerated and offers promising biological and clinicalactivity, said Jeffrey S. Heier, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Evolving glaucoma therapy: A new era of interventional strategies
2
Precision strategy: Optimizing visual outcomes with advanced small-aperture lenses
3
Throwback Series: Managing bilateral diabetic macular edema early in practice
4
ICYMI: AAO 2025 showcases new technologies and continued research
5

















































.png)


